GlassScriptPhysician profile
Navin Choudhary
NPI 1104913896
$3,216.20
in general payments reported to CMS, 2019-2025
20 companies · $841 in 2025
The $841 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.12 · 2020: $98.38 · 2021: $324 · 2022: $69.15 · 2023: $260 · 2024: $1,541 · 2025: $841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,641 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,641.19 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $742.53 | 2024-2025 | Fanapt |
| Amgen INC. | $418.36 | 2019-2025 | Repatha, Otezla |
| Eisai INC. | $391.88 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $293.89 | 2023-2024 | Breztri, Farxiga, Airsupra |
| Phathom Pharmaceuticals, INC. | $250.50 | 2024 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $227.10 | 2024 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $172.35 | 2022-2024 | |
| Novo Nordisk INC | $168.12 | 2021-2024 | Wegovy, Ozempic |
| Merck Sharp & Dohme LLC | $124.84 | 2024 | Verquvo |
| Corcept Therapeutics | $106.18 | 2023 | Korlym |
| Pfizer INC. | $77.79 | 2025 | |
| Astellas Pharma US INC | $67.81 | 2021-2024 | Veozah |
| Dexcom, INC. | $42.77 | 2022-2023 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $33.90 | 2023-2025 | Austedo Xr, Austedo Xr |
| Mallinckrodt Hospital Products INC. | $25.62 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $20.98 | 2021 | |
| Optos, INC. | $19.47 | 2021 | |
| Azurity Pharmaceuticals, INC. | $16.01 | 2024 | |
| Abbott Laboratories | $15.31 | 2023 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Navin Choudhary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.